Application 1029
Brachytherapy for the treatment of prostate cancer
Application No. | 1029 |
| Application Name | Brachytherapy for the treatment of prostate cancer |
| Advisory Panel | Dr Michael Kitchener (Chair and MSAC member) Dr Ross Cartmill (Royal Australasian College of Surgeons and the Urological Society of Australasia nominee) Mr Clive Deverall (Consumers' Health Forum of Australia nominee) Dr Graeme Dickie (Royal Australian and New Zealand College of Radiologists nominee) Associate Professor Gillian Duchesne (Royal Australian and New Zealand College of Radiologists nominee) Dr Alastair Tulloch (Urological Society of Australasia nominee) |
| Date Received by MSAC Secretariat | 1 November 1999 |
| Stage 1 - Eligibility | Eligible |
| Stage 2 - Assessment | Completed |
| Stage 3 - Formulation of Advice to the Minister | This assessment was considered by the MSAC at the 15 November 2000 meeting. The MSAC recommends that on the strength of evidence pertaining to brachytherapy for the treatment of prostate cancer, interim public funding should be supported for patients with prostate cancer meeting the following criteria: - at clinical stages T1, T2a or T2b, with Gleason Scores of less than or equal to 6, PSA of less than or equal to 10ng/ml, gland volume less than 40cc and with a life expectancy of more than 10 years; and - where the treatment is conducted at approved sites This recommendation is to be reviewed no later than three years from the date of this report. |
| Stage 4 - Decision | Endorsed by the Minister for Health and Ageing 9 February 2001 |
| Stage 5 - Implementation | Implemented |
Page currency, Latest update: 06 July, 2009
